Research Paper Volume 15, Issue 12 pp 5445—5481

Figure 9. Relationship between WM_Score and efficacy of immunotherapy. (A, B) Violin plots showing the WM_Score in patients with different responses to PD-L1 blockade in the Kim et al. immunotherapy cohort. Kruskal-Wallis tests were used to evaluate the significance. (C) Box plot showing the WM_Score in patients of different TCGA subtypes (Kruskal-Wallis test). (D) Kaplan–Meier curve showing the overall survival status of patients receiving PD-L1 blockade immunotherapy in the IMvigor210 cohort (p = 0.003, Log-rank test). (E) The proportion of patients responding to PD-L1 blockade immunotherapy in low and high WM_Score groups in the IMvigor210 cohort. SD, stable disease; PD, progressive disease; CR, complete response; PR, partial response. (F) Violin plot showing the WM_Score in patients with different responses to PD-L1 blockade immunotherapy in the IMvigor210 cohort. (G, H) Box plots showing the neoantigen burden (G) and mutational burden (H) of high and low WM_Score groups in the IMvigor210 cohort. Wilcoxon tests were used to evaluate the significance. (I) Kaplan–Meier curve showing the overall survival of high or low WM_Score patients with high or low TMB (p = 0.007, Log-rank test). (J) Kaplan–Meier curves showing the overall survival of high or low WM_Score patients with high or low neoantigen burden in the IMvigor210 cohort (p = 0.005, Log-rank test). (K) Kaplan–Meier curve showing the overall survival status of patients receiving PD1 blockade immunotherapy in high and low WM_Score groups in the Liu et al. immunotherapy cohort (p = 0.018, Log-rank test). (L) The proportion of patients responding to PD1 blockade immunotherapy in low and high WM_Score groups. SD, stable disease; PD, progressive disease; CR, complete response; PR, partial response. (M, N) Box plots showing the expression of PD-L1 (M) and CTLA4 (N) of high and low WM_Score groups. Wilcoxon tests were used to evaluate significance. (O) Kaplan–Meier curve showing the overall survival status of patients receiving anti-PD1 immunotherapy in high and low WM_Score groups in the GSE78220 cohort (p = 0.053, Log-rank test). (P) The proportion of patients responding to anti-PD1 immunotherapy in low and high WM_Score groups in the GSE78220 cohort. PD, progressive disease; CR, complete response; PR, partial response. (Q) Predictive value of the WM_Score in patients receiving anti-PD-1 immunotherapy in the GSE78220 cohort (AUC = 0.827).